Absci (ABSI)

The company works in the field of biologics, a category that includes antibodies and other complex protein therapeutics. Its technology combines generative AI, high-throughput screening, protein engineering, and wet-lab validation to design molecules and assess how they may perform as potential medicines. This approach is intended to help optimise characteristics such as binding, potency, manufacturability, and dosing convenience before candidates move deeper into preclinical or clinical development.

Absci develops internal programmes and may also collaborate with pharmaceutical and biotechnology companies seeking to use its platform for drug creation. Its lead product candidate, ABS-201, is described as an anti-prolactin receptor antibody engineered with an extended half-life, with the aim of supporting less frequent and more patient-friendly dosing. The company’s pipeline and partnerships are important because Absci remains primarily a technology-enabled drug discovery business rather than a mature commercial pharmaceutical company.

For investors, Absci offers exposure to the convergence of AI and biopharma research. Its prospects depend on the platform’s ability to generate differentiated biologic candidates, translate computational designs into viable medicines, and form development or commercial partnerships in a highly competitive sector.